High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition

Keyphrases

• Neuroblastoma Cell Line 100%
• Leukemia 100%
• Xenograft 100%
• Myeloid Cells 100%
• Venetoclax 100%
• ABT-199 100%
• B-cell Lymphoma 100%
• High Efficacy 100%
• Neuroblastoma 10%
• 2-complex 10%
• Family Protein 10%
• Neuroblastoma Cells 5%
• Cell Viability 5%
• Neuroblastoma Tumor 5%
• Apoptosis 5%
• Expression Level 5%
• Sequestration 5%
• Mitochondria 5%
• Oncogenesis 5%
• Anti-apoptotic 5%
• Anti-apoptotic Proteins 5%
• Growth Inhibition 5%
• Two-level 5%
• Combination Treatment 5%
• Apoptotic Response 5%
• In Vitro Inhibition 5%
• Cytochrome c Release 5%

Medicine and Dentistry

• Neuroblastoma Cell Line 100%
• Leukemia 100%
• Xenograft 100%
• Myeloid Cell 100%
• B-Cell Lymphoma 100%
• Venetoclax 100%
• Ganglioneuroblastoma 10%
• Antiapoptotic 10%
• Neuroblastoma Cell 5%
• Neoplasm 5%
• Cell Viability 5%
• Cell Line 5%
• Patient with Neuroblastoma 5%
• In Vitro 5%
• Carcinogenesis 5%
• Upregulation 5%
• Programmed Cell Death 5%
• Growth Inhibition 5%
• Mitochondrion 5%
• Protein Family 5%
• Protein Mcl 1 5%
• Cytochrome C 5%